Asset/brand planning for a cell therapy

Asset/brand panning for a cell therapy

Supporting a global pharmaceutical company to plan for the launch of a new cell therapy

Scope:

Global

Therapy area:

Orphan disease

Client:

Global pharmaceutical company

The Challenge

The client needed to align its priorities and resources for the launch of a new cell therapy for an orphan disease

Project objectives

To support the client in understanding the prelaunch critical success factors and priority tactics to prepare for the successful launch of a cell therapy for an orphan indication

Approach

A two-day virtual workshop was delivered leveraging in-depth pre-read materials to facilitate the identification of drivers/barriers for patient access, market externalities and critical success factors for launch. This was used to inform tactical objectives that were synthesised into a final asset plan

VALUE DELIVERED

The interactive workshop and production of the detailed asset plan enabled the team to plan effectively for the next 2-3 years prior to marketing authorisation, ensuring the launch teams and local markets are well positioned to maximise patient access for an important step change in therapy

Related case studies

Rapid market opportunity assessment for an ATMP

Supporting a global pharmaceutical company with a market opportunity assessment to support commercial decision making

Rapid multiple indication assessments

Rapid assessment of multiple ophthalmology orphan/non-orphan indications across the EU5 and the US

Cell and gene therapy landscape assessment

Global development landscape assessment of multiple ATMPs to support commercial decision making

Process development

Re-defining the opportunity assessment process for a global medical technology company

Full due-diligence process

Supporting a global medical device manufacturer with a full due-diligence assessment to support partner negotiations